Pharmacy Service, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
Section of Pediatric Hematology and Oncology, Department of Pediatrics, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
J Oncol Pharm Pract. 2021 Oct;27(7):1753-1757. doi: 10.1177/1078155220982046. Epub 2020 Dec 25.
Cerebellar mutism syndrome (CMS) is a common complication after posterior fossa tumor resection. It is characterized by a significant lack or loss of speech. Its biological origin remains unclear and there are no standardized treatments. However, bromocriptine seems to be a possible treatment for this condition.
In this paper, we present three cases of pediatric patients (4, 5, and 17-year old) who developed CMS after posterior fossa tumor surgery. They were treated with bromocriptine to improve neurological symptoms.Management and outcome: Bromocriptine was started at a low dose and was progressively increased to reach the minimum effective dose. After four months of treatment, a normal and fluid speech was observed in the three patients. No discontinuation due to adverse events were reported.
Bromocriptine has shown to be an effective and safe treatment for CMS in pediatric patients after posterior fossa tumor resection.
小脑缄默症（CMS）是后颅窝肿瘤切除术后的常见并发症。其特征为言语显著减少或丧失。其生物学起源尚不清楚，也没有标准化的治疗方法。然而，溴隐亭似乎是治疗这种疾病的一种可能方法。
本文介绍了 3 例儿童患者（4 岁、5 岁和 17 岁），他们在接受后颅窝肿瘤手术后出现 CMS。他们接受溴隐亭治疗以改善神经症状。
溴隐亭以低剂量开始，并逐渐增加至达到最小有效剂量。治疗四个月后，三名患者的言语均恢复正常、流畅。未因不良反应而停药。
溴隐亭已被证明是一种有效且安全的治疗方法，可用于后颅窝肿瘤切除术后的小儿 CMS 患者。
